1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Drugs In Development, 2022, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 19 and 11 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 7 and 3 molecules, respectively.
Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chikungunya Fever - Overview
- Chikungunya Fever - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chikungunya Fever - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chikungunya Fever - Companies Involved in Therapeutics Development
- Chikungunya Fever - Drug Profiles
- Chikungunya Fever - Dormant Projects
- Chikungunya Fever - Product Development Milestones
- Featured News & Press Releases
- Jun 21, 2022: Emergent BioSolutions announces publication of CHIKV VLP phase 2 safety and immunogenicity data in The Lancet Infectious Diseases
- Jun 09, 2022: Valneva to present on its single-shot chikungunya vaccine candidate, host symposium at NECTM8
- May 26, 2022: Valneva concludes lot-to-lot Phase III trial of chikungunya vaccine
- Mar 08, 2022: Valneva successfully completes pivotal phase 3 trial of single-shot chikungunya vaccine candidate
- Feb 22, 2022: Emergex awarded £490,525 UK aid grant by the Department of Health and Social Care to advance synthetic T cell vaccine candidate for chikungunya virus
- Jan 31, 2022: Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate
- Dec 21, 2021: Valneva announces positive lot-to-lot consistency trial results for its single-shot chikungunya vaccine candidate
- Nov 15, 2021: Valneva to present its chikungunya vaccine candidate at the ASTMH 2021 Annual Meeting
- Oct 18, 2021: Emergent commences Phase III trial of single-dose chikungunya vaccine
- Sep 13, 2021: Peer-reviewed publication supports arthritic disease modifying effects of PPS in chikungunya virus
- Aug 24, 2021: IVI and BBIL launch global Chikungunya vaccine phase II/III trial in Costa Rica
- Aug 05, 2021: Valneva announces positive phase 3 pivotal results for its single-shot chikungunya vaccine candidate
- Jul 07, 2021: Valneva awarded FDA breakthrough designation for its single-shot chikungunya vaccine candidate
- Jul 05, 2021: Valneva to host symposium on Chikungunya vaccine candidate VLA-1553 at 31st European Congress of Clinical Microbiology & Infectious Diseases
- Jun 10, 2021: Valneva completes recruitment for phase 3 lot-to-lot consistency trial of its Chikungunya Vaccine Candidate
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Chikungunya Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chikungunya Fever - Dormant Projects, 2022
- Chikungunya Fever - Dormant Projects, 2022 (Contd..1)
- Number of Products under Development for Chikungunya Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Activirosomes Ltd
- Auro Vaccines LLC
- Bharat Biotech Ltd
- BioNet-Asia Co Ltd
- Bow Therapeutics
- Ciloa
- Collaborations Pharmaceuticals Inc
- Emergent BioSolutions Inc
- Emergex Vaccines Holding Ltd
- Ennaid Therapeutics LLC
- Hawaii Biotech Inc
- ImmunityBio Inc
- Imophoron Ltd
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- Integrated BioTherapeutics Inc
- Medigen Inc
- Meletios Therapeutics SAS
- Merck & Co Inc
- Najit Technologies Inc
- Pai Life Sciences Inc
- Paradigm Biopharmaceuticals Ltd
- Precision Virologics Inc
- ProtInhi BV
- Riboscience LLC
- Sementis Ltd
- Shionogi & Co Ltd
- Takeda Pharmaceutical Co Ltd
- Technovalia Pty Ltd
- Valneva SE
- Vaxart Inc
- VenatoRx Pharmaceuticals Inc
